Table 1.
The 10 most cited papers on anti-PD1/PDL1 immunotherapy for cancers. a
| Rank | Title | Corresponding author | Year | Total citations | Average citations per year (rank) |
|---|---|---|---|---|---|
| 1 | Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer | Topalian, SL | 2012 | 7,983 | 833.0 (3) |
| 2 | Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Borghaei, H | 2015 | 5,521 | 883.4 (2) |
| 3 | Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer | Brahmer, JR | 2012 | 5,052 | 527.2 (11) |
| 4 | PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Diaz, LA | 2015 | 4,938 | 750.1 (4) |
| 5 | Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer | Brahmer, JR | 2016 | 4,866 | 941.8 (1) |
| 6 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Hodi, FS | 2015 | 4,791 | 737.1 (5) |
| 7 | Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Brahmer, J | 2015 | 4,405 | 677.7 (6) |
| 8 | Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer | Garon, EB | 2015 | 3,618 | 542.7 (10) |
| 9 | Nivolumab versus Everolimus in Advanced Renal-Cell Cancer | Motzer, RJ | 2015 | 3,453 | 559.9 (9) |
| 10 | Nivolumab in Previously Untreated Melanoma without BRAF Mutation | Robert, C | 2015 | 3,444 | 492.0 (14) |
a
These 10 papers were published in the New England Journal of Medicine.
PD1, programmed cell death 1; PDL1, programmed cell death 1 ligand 1.